Capivasertib, a protein kinase B (AKT) inhibitor, has demonstrated robust efficacy against hormone receptor–positive, human epidermal growth factor receptor type 2–negative advanced breast cancer, particularly in patients with AKT pathway mutations. This evidence concerns the gene NR4A1 and breast carcinoma.